Inactive Instrument

Other languages Mylan N.V. Nasdaq

Equities

MYL

NL0011031208

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Idorsia poursuit les discussions avec ses créanciers	Apr. 17
Idorsia bleibt weiter in einer finanziell schwierigen Lage	Apr. 17
Idorsia sucht weiter nach Lösung für finanziellen Engpass	Apr. 17
Viatris Inc. Appoints Corinne Le Goff as Chief Commercial Officer	Apr. 15
Viatris Inc. Announces Launch of First Bioequivalent Generic Version of Copaxone 20 mg/mL Once-Daily in Canada	Apr. 15
Ocuphire Pharma, Inc. Announces Global License Agreement with Viatris Inc	Apr. 11
UK's Theramex sees no impact to HRT products supply after CMA probe	Apr. 05
UK watchdog says Theramex-Viatris deal raises competition concerns	Apr. 04
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review	Apr. 01
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review	Apr. 01
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent	Apr. 01
Viatris Launches of Ryzumvi Eye Drops to Reverse Dilation in US	Apr. 01
Viatris Inc. Announces the Launch of RYZUMVI (Phentolamine Ophthalmic Solution) 0.75% in the United States	Apr. 01
Viatris Seeks M&A	Mar. 27
Los daños en el oleoducto de Sudán del Sur podrían agravar el conflicto en Sudán -- Market Talk	Mar. 27
Stonex Group Insider Sold Shares Worth $488,142, According to a Recent SEC Filing	Mar. 25
Idorsia-Aktien ziehen nach US-Zulassung für Blutdrucksenker an	Mar. 20
Bourse Zurich: les indices en rouge pour entamer la semaine	Mar. 18
Borsa svizzera: chiude in ribasso, SMI -0,45%	Mar. 18
Bourse Zurich: les investisseurs prudents avant la semaine des banques centrales	Mar. 18

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Mylan N.V. Nasdaq

Equities

MYL

NL0011031208

Other languages

Filters